Evidence map›Paper›PMID 35928266›Full record

ArticleFrontiers in pharmacology2022

Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques.

G J Gatto, A Krovi, L Li, I Massud, A Holder, J Gary, P Mills, J Mitchell, E Luecke, Z R Demkovich and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

G J GattoRTI International, Research Triangle Park, NC, United States.
A KroviRTI International, Research Triangle Park, NC, United States.
L LiRTI International, Research Triangle Park, NC, United States.
I MassudDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
A HolderDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
J GaryNeuropathology, StageBio, Frederick, MD, United States.
P MillsDepartment of Comparative Medicine, Tulane University, New Orleans, LA, United States.
J MitchellDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
E LueckeRTI International, Research Triangle Park, NC, United States.
Z R DemkovichRTI International, Research Triangle Park, NC, United States.
W HeneineDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
J G García-LermaDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
M A MarzinkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
R M BrandDepartment of Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
C W DobardDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States.
L M JohnsonRTI International, Research Triangle Park, NC, United States.
A Van Der StratenDepartment of Medicine, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco, CA, United States.
Centers for Disease Control and Prevention · USRTI International · USJohns Hopkins University · USTulane University · USUniversity of California, San Francisco · USUniversity of Pittsburgh · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
6 · The paper itself

Abstract

The administration of antiretrovirals (ARVs) for HIV pre-exposure prophylaxis (PrEP) is highly efficacious and may benefit from new long-acting (LA) drug delivery approaches. This paper describes a subcutaneous, reservoir-style implant for the LA delivery of tenofovir alafenamide (TAF) and documents the preclinical assessment of implant safety and pharmacokinetics (PK) in New Zealand White (NZW) rabbits (3 groups of

Indexed as

biodegradable polymercomparative pharmacokineticsHIV pre-exposure prophylaxisreservoir implantstenofovir alafenamide

Identifiers

PMID35928266
PMCPMC9343794
OpenAlexW4286218975

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.